BeOne Medicines Ltd. (ONC) Stock Chart - Revenue & Earnings | Quarter Chart

Select dashboard New custom dashboard
Income Statement

Revenue by Product

ProductCollaboration
0375M750M1B2B2B2B3B3BQ1 2025Q2 2025Q3 2025Q4 2025Q1 20260375M750M1B2B2B2B3B3BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue by Geography

UNITED STATESCHINAEurope
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 20260250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue, Gross Profit, Operating and Net Income

RevenueGross ProfitOperating IncomeNet Income
0500M1B2B2B2B3B4B4BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Margin (%)

Gross MarginOperating MarginNet Income Margin
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Operating Expenses

Research And Development Expenses
088M175M262M350M438M525M612M700MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EBITDA

EBITDA
050M100M150M200M250M300M350M400MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

EPS

EPSEPS Diluted
0815223038455260Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue Variation (%)

Revenue Variation
-12471012151720Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Variation (%)

Gross Profit VariationOperating Income VariationNet Income Variation
01K2K3K4K6K7K8K9KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Revenue YoY Variation (%)

Revenue YoY Variation
0815223038455260Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income YoY Variation (%)

Gross Profit YoY VariationOperating Income YoY VariationNet Income YoY Variation
04K8K11K15K19K22K26K30KQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Price-to-Earning Ratio

P/E Ratio
0100200300400500600700800Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Income Breakdown

Rule Of 40 (EBITDA)Rule Of 40 (FCF)
0255075100125150175200Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Per Share Metrics

Operating IncomeInterest IncomeTotal Other Income Expenses NetNet Income
075M150M225M300M375M450M525M600MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Expense Ratios

Revenue Per ShareNet Income Per ShareOperating Cash Flow Per Share
02581012151820Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Cash Flow Statement

Operating Cash Flow

Research And Ddevelopement To RevenueCapex To RevenueStock Based Compensation To Revenue
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Free Cash Flow

Operating Cash FlowCapital ExpenditureFree Cash Flow
0100M200M300M400M500M600M700M800MQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash Flow to Debt Ratio

Cash At End Of Period
0750M2B2B3B4B4B5B6BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Balance Sheet

Current Ratio

Net Cash Provided By Operating ActivitiesNet Cash Used Provided By Financing Activities
0250M500M750M1B1B2B2B2BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Quick Ratio

Total AssetsTotal Liabilities
02B5B8B10B12B15B18B20BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Cash & Equivalents

Total Current AssetsTotal Non Current Assets
01B2B3B4B6B7B8B9BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Total Assets

Total Current LiabilitiesTotal Non Current Liabilities
0625M1B2B2B3B4B4B5BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Total Liabilities

Total Stockholders Equity
0625M1B2B2B3B4B4B5BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Shareholders Equity

Debt To Equity
000001111Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Asset Composition

Cash And Cash Equivalents
0750M2B2B3B4B4B5B6BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026

Debt Structure

Short Term DebtLong Term Debt
0375M750M1B2B2B2B3B3BQ1 2025Q2 2025Q3 2025Q4 2025Q1 2026
Key Metrics

BeOne Medicines Ltd. (ONC) quarterly earnings & revenue

BeOne Medicines Ltd. (ONC) reported revenue of $1.51B for Q1 2026, up 35.5% year-over-year, with net income of $227.36M and diluted EPS of $25.35.

Over the last four reported quarters, BeOne Medicines Ltd. generated $5.74B in revenue and $513.02M in net income.

BeOne Medicines Ltd.'s next earnings report is scheduled for August 5, 2026 before market open; analysts estimate EPS of $1.57.

BeOne Medicines Ltd. quarterly results

Fiscal quarterRevenueRevenue YoYNet incomeEPS (diluted)
Q1 2026$1.51B+35.5%$227.36M$25.35
Q4 2025$1.50B+32.8%$66.50M$6.76
Q3 2025$1.41B+41.0%$124.84M$13.52
Q2 2025$1.32B+41.6%$94.32M$0.84
Q1 2025$1.12B+48.6%$1.27M$0.01
Q4 2024$1.13B+77.8%$-151.88M$-1.43
Q3 2024$1.00B+28.2%$-121.35M$-1.16
Q2 2024$929.17M+56.1%$-120.41M$-1.15

📈 Analysts estimate ONC EPS of $1.57 for the upcoming quarter. See BeOne Medicines Ltd. revenue & EPS analyst forecasts for the next four quarters with Quarter Chart Premium.

BeOne Medicines Ltd. (ONC) — frequently asked questions

When does BeOne Medicines Ltd. (ONC) report earnings next?

BeOne Medicines Ltd. is expected to report earnings on August 5, 2026 before market open. Analysts estimate EPS of $1.57.

What was ONC's revenue last quarter?

BeOne Medicines Ltd. reported revenue of $1.51B in Q1 2026, up 35.5% from the same quarter a year earlier.

What was ONC's EPS last quarter?

BeOne Medicines Ltd. reported diluted EPS of $25.35 in Q1 2026.

Is BeOne Medicines Ltd. profitable?

BeOne Medicines Ltd. is currently profitable, with $513.02M in net income over the last four reported quarters.

Compare with other Healthcare companies: Eli Lilly (LLY) · Johnson & Johnson (JNJ) · AbbVie (ABBV) · UnitedHealth (UNH) · Merck (MRK) · Roche (ROG.SW)